{"id":1580,"date":"2019-06-13T07:00:00","date_gmt":"2019-06-13T07:00:00","guid":{"rendered":"https:\/\/oncopeptides.com\/mfn_news\/oncopeptides-ab-oncopeptides-kommer-att-halla-en-webcast-mandagen-den-17-juni-klockan-0900-cet-for-genomgang-och-uppdatering-av-presentationer-fran-eha\/"},"modified":"2026-02-23T13:18:29","modified_gmt":"2026-02-23T13:18:29","slug":"oncopeptides-ab-oncopeptides-kommer-att-halla-en-webcast-mandagen-den-17-juni-klockan-0900-cet-for-genomgang-och-uppdatering-av-presentationer-fran-eha","status":"publish","type":"mfn_news","link":"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ab-oncopeptides-kommer-att-halla-en-webcast-mandagen-den-17-juni-klockan-0900-cet-for-genomgang-och-uppdatering-av-presentationer-fran-eha\/","title":{"rendered":"Oncopeptides AB: Oncopeptides kommer att h\u00e5lla en webcast m\u00e5ndagen den 17 juni klockan 09:00 (CET) f\u00f6r genomg\u00e5ng och uppdatering av presentationer fr\u00e5n EHA"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/p>\n<p class=\"mfn-wp-retain\">Stockholm &#8211; 13 juni 2019 &#8211; Oncopeptides AB (Nasdaq Stockholm: ONCO), meddelar idag att bolaget kommer g&ouml;ra en genomg&aring;ng och uppdatering kring de presenterade data fr&aring;n det europeiska hematologim&ouml;tet (EHA) m&aring;ndagen den 17 juni 2019, kl. 09:00 (CET).<\/p>\n<p><\/strong><\/div>\n<p class=\"mfn-wp-retain\">Detta kommer att presenteras av VD Jakob Lindberg och medlemmar ur Oncopeptides ledningsgrupp. &nbsp;<\/p>\n<p class=\"mfn-wp-retain\">Telefonkonferensen kan &auml;ven f&ouml;ljas via l&auml;nken <a href=\"https:\/\/tv.streamfabriken.com\/2019-06-17-oncopeptides-press-conference\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/tv.streamfabriken.com\/2019-06-17-oncopeptides-press-conference<\/a>.<\/p>\n<p class=\"mfn-wp-retain\">Telefonnummer f&ouml;r deltagare fr&aring;n:<br \/>Sverige: +46 8&nbsp;566&nbsp;427 06<br \/>Europa: +44&nbsp;333&nbsp;300 9030<br \/>USA: +1&nbsp;833&nbsp;526 8384<\/p>\n<p class=\"mfn-wp-retain\">F&ouml;r ytterligare information kontakta:<br \/>Rein Piir, chef f&ouml;r Investor Relations vid Oncopeptides<br \/>E-post: rein.piir@oncopeptides.com<br \/>Mobiltelefon: +46 (0) 70 853 72 92<\/p>\n<p class=\"mfn-wp-retain\">Information l&auml;mnades f&ouml;r offentligg&ouml;rande den 13 juni 2019 kl.09:00.<\/p>\n<p class=\"mfn-wp-retain\">Om Oncopeptides<br \/>Oncopeptides &auml;r ett l&auml;kemedelsf&ouml;retag med inriktning p&aring; utveckling av riktade terapier f&ouml;r sv&aring;rbehandlade hematologiska cancerformer. Bolaget fokuserar p&aring; utvecklingen av produktkandidaten melflufen, en lipofil peptidl&auml;nkad alkylerare, tillh&ouml;rande en ny l&auml;kemedelsklass kallad Peptidase Enhanced Cytotoxics (PEnC). Melflufen utvecklas som en ny behandling av den hematologiska cancersjukdomen multipelt myelom och testas f&ouml;r n&auml;rvarande i en pivotal fas 2-studie kallad HORIZON och en bekr&auml;ftande klinisk fas 3-studie kallad OCEAN d&auml;r rekrytering p&aring;g&aring;r. Oncopeptides har huvudkontor i Stockholm och &auml;r noterat i Mid Cap-segmentet p&aring; Nasdaq Stockholm med kortnamn ONCO.<\/p>\n<p class=\"mfn-wp-retain\">F&ouml;r mer information bes&ouml;k www.oncopeptides.com.<\/p>\n<div class=\"mfn-footer\"><\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><div class=\"mfn-attachment mfn-file-type-pdf\"><a class=\"mfn-attachment-link\" target=\"_blank\" href=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F2839426%2F1061801.pdf\" rel=\"noopener\"><span class=\"mfn-attachment-icon\"><img decoding=\"async\" src=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F2839426%2F1061801.pdf&type=jpg\"><\/span>PDF<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Stockholm &#8211; 13 juni 2019 &#8211; Oncopeptides AB (Nasdaq Stockholm: ONCO), meddelar idag att bolaget kommer g&ouml;ra en genomg&aring;ng och uppdatering kring de presenterade data fr&aring;n det europeiska hematologim&ouml;tet (EHA) m&aring;ndagen den 17 juni 2019, kl. 09:00 (CET). Detta kommer att presenteras av VD Jakob Lindberg och medlemmar ur Oncopeptides ledningsgrupp. &nbsp; Telefonkonferensen kan &auml;ven [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","news_categories":[],"mfn-news-tag":[174,171,180],"class_list":["post-1580","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news\/1580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=1580"}],"wp:term":[{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news_categories?post=1580"},{"taxonomy":"mfn-news-tag","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn-news-tag?post=1580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}